WE CLAIM:
[Claim 1] A compound of Formula (I) or a salt thereof:
(in the formula,
R1 is vinyl, (E)-l-propenyl or cyclopropyl, R2 is Formula (II) or (III), [Chem. 10]
R3 is C3-4 alkyl, methyl or n-propyl each of which may be substituted with two or more F's, ethyl or C3-4 cycloalkyl each of which may be substituted with F, benzyl which may be substituted with C1-3 alkyl, benzyl which may be substituted with -O-C1-3 alkyl, or benzyl which may be substituted with -0-(Ci-3 alkyl which is substituted with F), R4 is -O-C3-5 alkyl which may be substituted, -O-cycloalkyl which may be substituted, or Formula (IV), (V), (VI), or (VII), [Chem. 11]

Re is CChMe, COMe, CON(Me)2, SChMe, C3-4 cycloalkyl, a nonaromatic heterocyclic
group having 4 to 6 ring members which may be substituted, or C1-3 alkyl which may be
substituted with a group selected from the Group G,
the Group G is -O-C1-3 alkyl, -0-(Ci-3 alkyl which is substituted with F or C3-4 cycloalkyl),
C3-4 cycloalkyl, -F, -CN, -SChMe, an aromatic heterocyclic group, a nonaromatic
heterocyclic group having 4 to 6 ring members, -N(Ci-3 alkyl)2, and -C(Me)20H,
Rf is H, methyl, or F,
Rg is H, methyl, or ethyl,
Rh is C1-3 alkyl which may be substituted with -OMe,
X is O, NH, S, or methylene,
Y is a bond or methylene,
Z is a bond, methylene, or ethylene,
Q is methylene or ethylene,
n is an integer of 1 or 2, and
m is an integer in a range of 1 to 3.)
[Claim 2] The compound or the salt thereof according to claim 1,
wherein R2 is Formula (II).
[Claim 3] The compound or the salt thereof according to claim 2,
wherein R4 is Formula (IV).
[Claim 4] The compound or the salt thereof according to claim 3,
wherein X is O.
[Claim 5] The compound or the salt thereof according to claim 4,
wherein R5 is H.
[Claim 6] The compound or the salt thereof according to claim 5,
wherein R1 is vinyl or cyclopropyl.
[Claim 7] The compound or the salt thereof according to claim 6,
wherein Ra is H, Rb is H or F, Rc is methyl or CI, and Rd is H.
[Claim 8] The compound or the salt thereof according to claim 7y
wherein R3 is C3-4 alkyl, methyl or n-propyl each of which is substituted with two or more F's, or ethyl or C3-4 cycloalkyl each of which may be substituted with F.

[Claim 9] The compound or the salt thereof according to claim 8,
wherein Re is a nonaromatic heterocyclic group having 4 to 6 ring members which may be substituted, or C1-3 alkyl which may be substituted with a group selected from the Group G.
[Claim 10] The compound or the salt thereof according to claim 9,
wherein Re is oxetanyl, tetrahydropyranyl, or C1-3 alkyl which may be substituted with a group selected from the group consisting of -OMe, -OEt, and -C(Me)20H.
[Claim 11] The compound or the salt thereof according to claim 1,
wherein the compound is selected from the group consisting of (+)-l-(7-{8-ethoxy-7-(5-methyl-lH-indazol-4-yl)-2-[(l-methylpiperidin-4-yl)oxy]-6-vinylquinazolin-4-yl}-2,7-diazaspiro[3.5]non-2-yl)prop-2-en-l-one, (+)-1 - { 7- [6-cyclopropyl-2- {[ 1 -(2-methoxyethyl)piperidin-4-yl] oxy } -7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-l-one,
(+)-1 - { 7-[2- {[ 1 -(2-methoxyethyl)piperidin-4-yl] oxy} -7-(5 -methyl-1 H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-l-one,
(+)-1 - { 7- [2- {[ 1 -(2-ethoxyethyl)piperidin-4-yl] oxy} -7-(5-methyl-1 H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-l-one,
(+)-l-{7-[6-cyclopropyl-2-{[l-(3-methoxypropyl)piperidin-4-yl]oxy}-7-(5-methyl-lH-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-l-one,
(+)-1 - { 7- [7-(5 -methyl-1 H-indazol-4-yl)-2- {[ 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]oxy}-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl} prop-2 -en-1 -one, and
(+)-1 - { 7-[2- {[ 1 -(2-hydroxy-2-methylpropyl)piperidin-4-yl] oxy} -7-(5-methyl-1 H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-l-one.
[Claim 12] A pharmaceutical composition, comprising:
the compound or the salt thereof according to claim 1; and a pharmaceutically acceptable excipient
[Claim 13] The pharmaceutical composition according to claim 12 which is a
pharmaceutical composition for treating lung cancer.

[Claim 14] Use of the compound or the salt thereof according to claim 1 for the
manufacture of a pharmaceutical composition for treating lung cancer.
[Claim 15] The compound or the salt thereof according to claim 1 for use in the
treatment of lung cancer.
[Claim 16] Use of the compound or the salt thereof according to claim 1 for treating
lung cancer.
[Claim 17] A method of treating lung cancer, comprising:
administering an effective dose of the compound or the salt thereof according to claim 1 to a target.